Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen’s Trebananib Meets First Phase III Goal In Ovarian Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen’s trebananib (AMG 386) meets progression-free survival endpoint in Phase III TRINOVA-1 recurrent ovarian cancer study, but higher dropout rate than expected needs explanation. Company also moves IL-17 inhibitor brodalumab into Phase III for psoriatic arthritis.

Advertisement

Related Content

Avastin Ovarian Cancer Approval Brings Some Clarity On PFS Endpoint
Amgen’s Melanoma Vaccine Shows Durable Response; Survival Still A Hurdle
Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into
Genentech Likely To Wait For Survival Data For U.S. Filing Of Avastin In Ovarian Cancer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075812

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel